Broad/Dana-Farber

Advancing Immunotherapy Research

Researchers in Dana-Farber’s Center for Neuro-Oncology are now launching attacks on glioblastomas from a new angle – by turning the patient’s immune system against the cancer cells. Where targeted chemotherapy uses drugs to disable proteins that cancer cells need to grow, immunotherapy drugs stimulate the patient’s immune system to recognize and kill cancer cells.

Developing an individualized vaccine relies upon understanding the unique molecular characteristics of a patient’s tumor.  In order to do this, Accelerate Brain Cancer Cure is funding the whole exome sequencing of NeoVax tumors at the Broad Institute.  This rigorous level of analysis will help Dana-Farber researchers tailor the vaccine to the immunogenic signatures found within the tumor.

 

Share |

Join us in our fight for a cure!